« Return to News | Drug Sponsors

Xention, Ono continue collaboration

Tuesday, April 12, 2011 11:21 AM

Xention, a Cambridge, U.K.-based biopharmaceutical company that discovers and develops ion channel-modulating drugs, will extend its collaboration with Ono Pharmaceutical.  The two-year agreement between the companies began in March 2009.  The collaboration has been successful in identifying multiple compounds that selectively modulate the function of target ion channels, and the two have agreed to extend the drug-discovery collaboration for another year.

Xention is applying its proprietary ion channel drug discovery platform to the identification, design and synthesis of small molecules against ion channels selected by Ono.  Ono is responsible for subsequent pre-clinical, clinical development and worldwide commercialization of potential new pharmaceutical products arising from the collaboration.

Ono will continue to fund the research program in its entirety, and Xention will receive milestone fees on meeting specified drug-discovery targets and on Ono’s achievement of development and regulatory goals.  Xention will also receive royalties on the sales of successfully commercialized products.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.